Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial

Journal article

Peer reviewed

Pietro Invernizzi, Marco Carbone, David Jones, Cynthia Levy, Nicola Little, Philippe Wiesel, Frederik Nevens and the study investigators

Liver international

2023-05-15

PMID: 37183520

Metrics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.125 Hepatitis; 1.125.1515 Primary Biliary Cirrhosis
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo‐controlled, phase 2 trial
Creators: Pietro Invernizzi - University of Milano-Bicocca
Marco Carbone - University of Milano-Bicocca
David Jones - Newcastle University
Cynthia Levy - University of Miami
Nicola Little - Calliditas Therapeutics AB, Stockholm, Sweden.
Philippe Wiesel - Genkyotex
Frederik Nevens - KU Leuven
the study investigators
Publication Details: Liver international
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hepatology
Language: English
Resource Type: Journal article
PMID: 37183520
Record Identifier: 991031800617802976